Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
13. Februar 2025 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
06. Februar 2025 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
05. Februar 2025 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Modified intent-to-treat group demonstrated +22.7 point (p<0.0001) treatment effect in the mean Bayley-III cognitive raw score compared to natural history data (ages 24-60 months) Older children...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17. Januar 2025 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
12. Januar 2025 11:00 ET
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89...
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
06. Januar 2025 02:00 ET
|
Ultragenyx Pharmaceutical Inc.
BASEL, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20. Dezember 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
20. Dezember 2024 03:00 ET
|
Ultragenyx Pharmaceutical Inc.
INTENDED FOR USE WITH MEDICAL MEDIA IN THE UK ONLYLONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and...
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
19. Dezember 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study...